![Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 | MMWR Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7130a4-F-large.gif?_=37269)
Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 | MMWR
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://www.thelancet.com/cms/attachment/db5c63dc-ee49-4b78-b05c-e93ffa8229af/gr1_lrg.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What](https://www.mdpi.com/vaccines/vaccines-10-01924/article_deploy/html/images/vaccines-10-01924-g001.png)
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table](https://covid19-sciencetable.ca/wp-content/uploads/2020/12/Figure-1.jpg)
Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table
![COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/372ade5e-5f14-48a9-b960-4b5767839337/gr1_lrg.jpg)
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases
![Frontiers | Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China Frontiers | Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China](https://www.frontiersin.org/files/Articles/834572/fpubh-10-834572-HTML/image_m/fpubh-10-834572-g001.jpg)
Frontiers | Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China
![Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile | Nature Communications Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-023-41942-y/MediaObjects/41467_2023_41942_Fig1_HTML.png)
Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile | Nature Communications
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://www.thelancet.com/cms/attachment/97d1c5ff-af79-4d10-b5b8-3026a35a572d/gr1_lrg.jpg)